Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
Study design (if review, criteria of inclusion for studies)
randomized trial
Participants
21 patients with cystic fibrosis and chronic Pseudomonas lung infection
Interventions
ceftazidime, 150 mg/kg/day, or with piperacillin, 300 mg/kg/day, and tobramycin, 10 and more mg/kg/day for 14 days
Outcome measures
On admission and at discharge, body weight, erythrocyte sedimentation rate, white blood cell count, and differential were determined. Pulmonary function analysis and chest X-rays were also obtained on both occasions as was sputum bacteriology. After hospitalization, the patients were followed in the outpatient department for 14-26 months.
Main results
Both treatments were associated with significant improvement in most of the parameters that were studied, but neither treatment was superior.